Phase 1Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity
A Randomized, Double-blind, Placebo-controlled First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of MBX 4291 in Adult Participants With Obesity
- Sponsor
- MBX Biosciences (Industry)
- Enrollment
- 124 planned
- Conditions
- Obesity
- Interventions
- MBX 4291; Placebo
- Ages
- adults, older adults
- Registry
- NCT07142707
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to evaluate the safety and tolerability of single and multiple subcutaneous (SC) doses of MBX 4291 in adults with obesity.
Primary outcomes
- Number of participants with Treatment Emergent Adverse Events (TEAEs)
History
Primary completion
Last registry update
Started
Registered